VIA
STOK icon

Virtus Investment Advisers’s Stoke Therapeutics STOK Stock Holding History

Virtus Investment Advisers’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$359K Buy
10,973
+2,555
+30% +$82K 0.08% 339
2026
Q1 		$274K Buy
8,418
+204
+2% +$6.69K 0.08% 295
2025
Q4 		$261K Sell
8,214
-1,413
-15% -$42.5K 0.07% 309
2025
Q3 		$226K Buy
9,627
+1,672
+21% +$28.6K 0.06% 251
2025
Q2 		$90.3K Sell
7,955
-5,368
-40% -$51K 0.03% 376
2025
Q1 		$88.6K Buy
+13,323
New +$124K 0.02% 437

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Virtus Investment Advisers's STOK Position: Q2 2026 in Review

Virtus Investment Advisers increased its Stoke Therapeutics (STOK) stake by 30% in Q2 2026, buying an estimated $82K and bringing the position to 10,973 shares worth $359K. The position accounts for 0.08% of the portfolio, ranked #339.

Virtus Investment Advisers first reported a position in STOK in Q1 2025 and has held it in 6 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Virtus Investment Advisers held 10,973 shares of Stoke Therapeutics worth $359K as of Q2 2026.
  • Virtus Investment Advisers bought 2,555 Stoke Therapeutics shares in Q2 2026, an estimated $82K.
  • Stoke Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q2 2026, its #339 holding.
  • Virtus Investment Advisers first reported a position in Stoke Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.